Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revvity Inc (RVTY)

Revvity Inc (RVTY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Revvity's Next Quarterly Earnings Report

Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $10 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal first-quarter earnings for 2026 in the near term.

Ahead of the event, analysts expect RVTY to report a profit of $1.02 per share on a diluted basis, up 1% from $1.01 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates...

Fundamentals

See More
  • Market Capitalization, $K 10,038,792
  • Shares Outstanding, K 111,803
  • Annual Sales, $ 2,856 M
  • Annual Income, $ 241,200 K
  • EBIT $ 357 M
  • EBITDA $ 767 M
  • 60-Month Beta 1.13
  • Price/Sales 3.54
  • Price/Cash Flow 10.26
  • Price/Book 1.41

Options Overview Details

View History
  • Implied Volatility 49.64% (-4.67%)
  • Historical Volatility 33.77%
  • IV Percentile 92%
  • IV Rank 62.21%
  • IV High 63.49% on 10/20/25
  • IV Low 26.84% on 06/17/25
  • Expected Move (DTE 5) 5.71 (6.36%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 580
  • Volume Avg (30-Day) 663
  • Put/Call OI Ratio 9.45
  • Today's Open Interest 10,692
  • Open Int (30-Day) 8,551
  • Expected Range 84.08 to 95.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $1.02
  • Number of Estimates 7
  • High Estimate $1.03
  • Low Estimate $1.01
  • Prior Year $1.01
  • Growth Rate Est. (year over year) +0.99%

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.48 +7.56%
on 03/13/26
92.99 -3.44%
on 04/08/26
-0.51 (-0.56%)
since 03/10/26
3-Month
83.48 +7.56%
on 03/13/26
118.30 -24.10%
on 01/22/26
-14.64 (-14.02%)
since 01/09/26
52-Week
81.36 +10.36%
on 09/04/25
118.30 -24.10%
on 01/22/26
-3.23 (-3.47%)
since 04/10/25

Most Recent Stories

More News
What to Expect From Revvity's Next Quarterly Earnings Report

Revvity will release its first-quarter earnings soon, and analysts anticipate a low single-digit bottom-line growth.

XLV : 147.31 (-1.35%)
$SPX : 6,816.89 (-0.11%)
RVTY : 89.79 (-0.74%)
Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the...

RVTY : 89.79 (-0.74%)
Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Scalable collaboration for biotech and pharma teams: Enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing Integrated,...

RVTY : 89.79 (-0.74%)
Is Revvity Stock Underperforming the S&P 500?

Revvity has lagged the broader S&P 500 over the past year, though analysts maintain a cautiously positive outlook on its forward growth potential.

$SPX : 6,816.89 (-0.11%)
RVTY : 89.79 (-0.74%)
DHR : 189.61 (-1.75%)
Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)

Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)

RVTY : 89.79 (-0.74%)
Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)

Research Tools & Consumables Stocks Q4 Results: Benchmarking Revvity (NYSE:RVTY)

RVTY : 89.79 (-0.74%)
Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know

Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know

ELAN : 23.13 (-1.41%)
AZTA : 22.21 (-1.99%)
AVTR : 7.90 (-0.25%)
THC : 195.24 (-3.28%)
RVTY : 89.79 (-0.74%)
2 Cash-Producing Stocks for Long-Term Investors and 1 We Find Risky

2 Cash-Producing Stocks for Long-Term Investors and 1 We Find Risky

AYI : 278.45 (+0.60%)
EPAM : 122.47 (-1.11%)
RVTY : 89.79 (-0.74%)
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know

Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know

MEDP : 493.53 (-1.59%)
TECH : 55.54 (-0.05%)
OSCR : 14.45 (-0.62%)
AZTA : 22.21 (-1.99%)
RVTY : 89.79 (-0.74%)
Do Wall Street Analysts Like Revvity Stock?

Although Revvity has lagged behind the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

XLV : 147.31 (-1.35%)
$SPX : 6,816.89 (-0.11%)
RVTY : 89.79 (-0.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software,...

See More

Key Turning Points

3rd Resistance Point 92.45
2nd Resistance Point 91.82
1st Resistance Point 90.81
Last Price 89.79
1st Support Level 89.17
2nd Support Level 88.54
3rd Support Level 87.53

See More

52-Week High 118.30
Fibonacci 61.8% 104.19
Fibonacci 50% 99.83
Fibonacci 38.2% 95.47
Last Price 89.79
52-Week Low 81.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.